Short answer: regular Medicare Part D still doesn't cover GLP-1 drugs for weight loss alone. But since 1 July 2026, the Medicare GLP-1 Bridge lets eligible people with Part D get Wegovy, Foundayo or the Zepbound KwikPen for weight management for $50 a month, with prior authorization.
Part D can also cover GLP-1s prescribed for type 2 diabetes, moderate-to-severe sleep apnea (Zepbound), MASH, or Wegovy to lower heart-attack and stroke risk, under your plan's usual rules.
What Part D covers in 2026
By law, Part D plans can't cover drugs used only for weight loss. They can cover a GLP-1 when it's prescribed for another approved use. CMS lists type 2 diabetes, moderate-to-severe obstructive sleep apnea (Zepbound), noncirrhotic MASH, and Wegovy prescribed to reduce the risk of heart attack and stroke. Your plan's formulary, prior authorization rules and normal cost-sharing apply. The Part D out-of-pocket cap is $2,100 in 2026 and rises to $2,400 in 2027.
The $50 Medicare GLP-1 Bridge
The Bridge is a temporary CMS program running from 1 July 2026 to 31 December 2027. It covers GLP-1s for weight management for a flat $50 a month. That $50 doesn't count toward your Part D deductible or out-of-pocket cap.
- Drugs: Wegovy pens and pills, Foundayo, and the Zepbound KwikPen. Zepbound vials and single-dose pens aren't included.
- Coverage you need: Part D through a standalone drug plan or a Medicare Advantage plan with drug coverage, including employer group plans and Special Needs Plans. Private fee-for-service plans, cost plans and PACE aren't included.
- Clinical criteria: age 18 or over and a BMI of 35 or more; or a BMI of 30 or more with heart failure with preserved ejection fraction, uncontrolled high blood pressure despite two medicines, or stage 3a or worse kidney disease; or a BMI of 27 or more with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
- Who's excluded: people with type 2 diabetes, moderate-to-severe sleep apnea or MASH, and anyone already getting a GLP-1 through their Part D plan. They stay on regular Part D coverage.
- How approval works: prior authorization starts at the pharmacy and then goes to your prescriber. CMS says there's no appeals process, and refills don't need re-approval.
CMS has also said the Part D part of its separate BALANCE model is delayed for 2027.
If you don't qualify, or prefer not to use Medicare
Many adults over 60 don't meet the Bridge criteria, have a plan type that isn't included, or want a different medication. Goprolean offers compounded semaglutide and tirzepatide as a cash-pay service, prescribed only if a licensed physician decides it's appropriate after reviewing your intake. Compounded medications are not FDA-approved and are not Wegovy or Zepbound. Nothing is billed to Medicare.
Adults 60 and over can verify with VerifyPass for 10% off their first order and every refill.
See compounded semaglutide and compounded tirzepatide for full details, safety information and plans.
Common questions
Does Medicare cover Wegovy for weight loss in 2026?
What is the Medicare GLP-1 Bridge?
Who qualifies for the $50 Medicare GLP-1 Bridge?
Does Medicare cover Zepbound?
Can I use Medicare at Goprolean?
Related
- Does TRICARE cover Wegovy or Zepbound?
- VA weight loss medication
- FEP Blue and FEHB coverage
- Weight loss on night shift
- Training clients on GLP-1s
- TRICARE and VA testosterone coverage
- Shift work and low testosterone
- Sermorelin: evidence and drug-testing rules
- NAD+ injections: what the evidence shows
- All verified discounts
Cash-pay service. Goprolean is a cash-pay service. We don't bill Medicare, Medicaid, TRICARE, the VA, the Federal Employees Health Benefits Program or any insurer, and nothing you buy here is submitted to a government health program. The verified-community discount is a cash discount on Goprolean's own prices. It isn't insurance and can't be combined with other offers.
No affiliation. Goprolean isn't affiliated with or endorsed by Medicare/CMS, the Department of Defense, TRICARE, the Department of Veterans Affairs, OPM, any employer or any health plan. Eligibility is verified by VerifyPass.
Coverage information is general, was checked on 8 November 2026, and plans change. Ask your plan about your own coverage.
Compounded medications. Compounded semaglutide and tirzepatide are prepared by a licensed pharmacy for an individual patient. They are not FDA-approved, have not been reviewed by the FDA for safety or effectiveness, and are not Wegovy®, Ozempic®, Zepbound® or Mounjaro®. Wegovy® and Ozempic® are registered trademarks of Novo Nordisk; Zepbound® and Mounjaro® are registered trademarks of Eli Lilly and Company. Goprolean isn't affiliated with either company.
Physician review. Prescriptions are issued only after a medical intake is reviewed by a licensed physician, who may determine that treatment is not appropriate, in which case the order is cancelled and you're refunded in full. Individual results vary. Pay over time with Klarna, subject to approval.
Goprolean is the telehealth and pharmacy service of Prolean Wellness, Scottsdale, Arizona. Is Goprolean legitimate? · How we handle health information · Privacy · Terms